FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use FRC

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Company ProfileDelivra Health Brands Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
DHBUF
Delivra Health Brands Inc. Stock AnalysisComprehensive stock analysis for Delivra Health Brands Inc. (DHBUF) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisDHBUF
DHBUF
Delivra Health Brands Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
DHBUF
Home🔹Stocks🔹Delivra Health Brands Inc.

Delivra Health Brands Inc.

🇺🇸DHBUF•OTC

Delivra Health Brands Inc.

🇺🇸DHBUF•OTC
Market cap
$4.10M
Sentiment

Your view on DHBUF

Mkt Cap
$4.10M
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Delivra Health Brands Inc.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Gord Davey
Headquarters
999 Canada Place, Vancouver, BC, CA
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Gord Davey
Headquarters
999 Canada Place, Vancouver, BC, CA
Description

Delivra Health Brands Inc. through its subsidiaries, provides lifestyle and wellness products to consumers and patients in regulated markets worldwide. It is involved in selling of cannabis, liquid sleep shots, sleep powder packets, and pain relief creams. The company is headquartered in Vancouver, Canada.

FRC Research

Research Reports

FRC analyst coverage and recommendations.

Past Reports

Historical coverage archive.

Analyst Notes

Ongoing commentary and updates from FRC analysts.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks it is worth vs. the current price.

FRC's fair value estimate for Delivra Health Brands Inc., and the rating behind it. DHBUF last traded at $0.13; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for Delivra Health Brands Inc.. Starting points for Delivra Health Brands Inc.: EPS -$0.03, beta 0.65 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for Delivra Health Brands Inc.. Delivra Health Brands Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for Delivra Health Brands Inc.. Trailing twelve-month EPS for Delivra Health Brands Inc. stands at -$0.03. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for Delivra Health Brands Inc.. Delivra Health Brands Inc. has reported as a listed company since 2017. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Delivra Health Brands Inc. valued side by side against its closest peers. Delivra Health Brands Inc. is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Premium

Which funds and firms own the stock.

Which institutions hold Delivra Health Brands Inc., and how their positions are changing. At a $4.1M market value, institutional positions materially move Delivra Health Brands Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Insider Trading

Premium

Recent buying and selling by company executives.

Buying and selling by Delivra Health Brands Inc. executives and directors. Shares of Delivra Health Brands Inc. have traded between $0.0057 and $0.26 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

Senate Trading

Premium

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming Delivra Health Brands Inc.. Delivra Health Brands Inc. is a $4.1M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

House Trading

Premium

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming Delivra Health Brands Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

News

Latest headlines and market coverage.

Latest headlines and company announcements for Delivra Health Brands Inc.. Coverage tracks Delivra Health Brands Inc. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

Peer companies

  • AYRWFAyr Wellness Inc.
  • AYURFAyurcann Holdings Corp.
  • CBIHCannabis Bioscience International Holdings, Inc.
  • CLCFFChristina Lake Cannabis Corp.
  • CVSICV Sciences, Inc.
  • HYEXHealthy Extracts Inc.
  • IONKFIonic Brands Corp.

More Drug Manufacturers - Specialty & Generic companies

  • BIOGYBioGaia AB (publ)
  • BIOIFBiome Grow Inc.
  • BKUHBakhu Holdings, Corp.
  • BLEVFBeleave Inc.
  • BMCSBioTech Medics, Inc.
  • BMMJBody and Mind Inc.
  • BNXT.CNBioNxt Solutions Inc.
  • BOIRFBoiron S.A.
  • BP8.AXBPH Global Ltd
  • BSPKBespoke Extracts, Inc.
  • BSPMBiostar Pharmaceuticals, Inc.
  • BUDZWEED, Inc.
DHBUF Analysis
Fair
Past1
Growth4
Health3
Profit1
Value1

Research Reports

9 reports

FRC previously covered Delivra Health Brands Inc. The reports below were published during active coverage.

Nov 19, 2025

Positive EPS Turnaround and Expansion Plans

DHB’s share price has risen 93% YTD, sharply outperforming the S&P Personal Care Index’s 11% decline.

Thumbnail for Positive EPS Turnaround and Expansion Plans
Oct 9, 2025

FY2025 Beat: Geographic Expansion and Potential M&A in the Works

Delivra Health Brands (TSXV: DHB / OTCQB: DHBUF) FY2025 revenue +8% YoY, share price +93%. Strong U.S./Middle East sales; expanding to Latin America.

Thumbnail for FY2025 Beat: Geographic Expansion and Potential M&A in the Works
May 30, 2025

Navigating Tariffs via Diversified Manufacturing & Geographic Expansion

Delivra Health Brands (DHB) grows 50% in 2025, outperforming peers. Diversified manufacturing mitigates tariffs. Dream Water, LivRelief drive sales at 30k+ retail points.

Thumbnail for Navigating Tariffs via Diversified Manufacturing & Geographic Expansion
    1
  • 1
  • 2
  • 3
3 reports
Dec 29, 2023

Doubles Revenue in Q1/Gearing Up for U.S. Product Launch

PDF
Oct 26, 2023

EBITDA Turns Positive/Gearing Up for U.S. Product Launch

PDF
Sep 12, 2023

A Health & Wellness Company Endorsed by Major Retail/Pharmacy Chains – Initiating Coverage

PDF
2 notes
Nov 19, 2025· 11 months agoLatest

Company announcement

Announces Q1 results (quarter ended September 2025)

Read the announcement
FRC Analyst's Comment
Opinion: Neutral - DHB’s revenue rose slightly by 1% to $3.21M, while EPS improved from $(0.02) to $(0.003), nearly reaching breakeven. Revenue came in below our expectations, reflecting typical quarterly fluctuations due to timing of large customer orders, while EPS was in line. DHB distributes sleep aid and pain relief products across 30,000+ points, including retail and pharmacy chains, convenience stores, and airports. We will publish an update shortly.
Mar 17, 2025· 1y ago

Company announcement

Launches a six-count sleep gummies product into the Canadian market

Read the announcement
FRC Analyst's Comment
Positive - This product launch (primarily targeting travelers) builds on the positive reception of DHB's 60-count Dream Water® Gummies, launched in Canada in 2024. The new product will be available nationwide through established retail and e-commerce partners. We note that the 60-count product has received favorable reviews, and strong ratings, on Amazon (NASDAQ: AMZN). Q2-FY2025 (ended December 2024) revenue was up 34% YoY. We believe FY2025 revenue will be driven by organic growth and new products like Dream Water Sleep Gummies and Dream Water Immunity Shots, supported by increasing awareness of sleep’s role in physical and mental health. DHB is trading at just 0.25x revenue, while comparable Personal Care companies trade at 1.20x on average, a 79% discount.

News

Latest Market News

No comments yet

Be the first to ask a question or say what you make of Delivra Health Brands Inc.